How to enhance value and access across pharma

Season 03: episode 11

This week, the GOLD team shares a conversation with Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson.

He discusses his lengthy career within value and access and his drive to enter the industry, his proudest achievements while working at J&J and the importance of having a good leader to learn from.


And in news you might have missed, the team showcases some recent investment in the psychedelics market, a first-in-10-years paediatric vaccine and a new study investigating the prevalence of undiagnosed CKD.


A little more on GOLD’s guest…


Chistoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson, holds market access very close to his heart. Appointed in this role in October 2021, he focuses on real-world value and evidence, pricing, reimbursement and more to connect medicines and treatments to those that need it most. He has spent over 20 years at J&J, and before this earned his Diplom-Kaufmann in his native Germany.


Additional resources


If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:

Click here to subscribe to the weekly newsletter for more insights from GOLD.